Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Drug Discovery Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.
The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.
In recent years, there has been a rising demand for specialty medicines that is expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the specialty medicines are small molecules.
The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.
Scope of the Report
As per the scope of the report, drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming.
Key Market Trends
Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type
A biologic drug is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms. Biologic drugs are used for the treatment of numerous diseases and conditions and are the most advanced therapies available. Biologic treatments are for autoimmune diseases, which include the treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and a range of related disorders, and have continued to see increasing usage across geographies. The biologic drugs are expected to be fueled by innovations in oncology, autoimmune, and diabetes treatments, with particular important opportunities for biologics in the oncology and autoimmune sectors.
The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Moreover, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies that are contributing to the market growth. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.
Competitive Landscape
The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of a Diverse Range of Diseases
4.2.2 Technological Advancements and Innovations
4.2.3 Increasing Healthcare Expenditure
4.2.4 Patent Expiration of Blockbuster Drugs
4.3 Market Restraints
4.3.1 Huge Capital Investment with Low-profit Margins
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Drug Type
5.1.1 Small Molecule Drug
5.1.2 Biologic Drug
5.2 By Technology
5.2.1 High Throughput Screening
5.2.2 Biochips
5.2.3 Bioinformatics
5.2.4 Pharmacogenomics and Pharmacogenetics
5.2.5 Combinatorial Chemistry
5.2.6 Nanotechnology
5.2.7 Spectroscopy
5.2.8 Metabolomics
5.2.9 Other Technologies
5.3 By Service
5.3.1 Drug Metabolism and Pharmacokinetics (DMPK) Services
5.3.2 Pharmaceutical Services
5.3.3 Chemical Services
5.3.4 Biological Services
5.4 By End User
5.4.1 Research Institutes
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations(CROs)
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 GlaxoSmithKline PLC
6.1.3 Merck & Co. Inc.
6.1.4 Agilent Technologies Inc.
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Bayer AG
6.1.8 Abbott
6.1.9 AstraZeneca PLC
6.1.10 Shimadzu Corp.
7. Market Opportunities and Future Trends
By Drug Type
- Small Molecule Drug
Biologic Drug
By Technology
High Throughput Screening
Biochips
Bioinformatics
Pharmacogenomics and Pharmacogenetics
Combinatorial Chemistry
Nanotechnology
Spectroscopy
Metabolomics
Other Technologies
By Service
Drug Metabolism and Pharmacokinetics (DMPK) Services
Pharmaceutical Services
Chemical Services
Biological Services
By End User
Research Institutes
Pharmaceutical Companies
Contract Research Organizations(CROs)
Other End Users - Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Duchenne Muscular Dystrophy Treatment Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.
Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment.
The rising prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis, and increasing healthcare insurance coverage are the major factors likely to accelerate the growth of the market. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.
Furthermore, with increasing awareness among people and with the government’s urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.
Scope of the Report
As per the scope of the report, Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.
Key Market Trends
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Grow Fastest During the Forecast Period
Corticosteroids are the only known pharmacological treatment for DMD and help to suppress muscle inflammation. This treatment is being limited by its inadequate therapeutic efficacy, and considerable side effects, and hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce the inflammation of muscles. The nonsteroidal anti-inflammatory drugs are expected to witness a CAGR of 49.2% over the forecast period.
However, other therapies and treatments include stem cell therapy, repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing (CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort have been used for the treatment of Duchenne muscular dystrophy, which is expected to drive the growth of the market, over the forecast period.
North American Region holds the Largest Market Share of the Market Currently and is Believed to Follow the Same Trend Over the Forecast Period
North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with the increasing clinical trials around the world, especially in the United States and Europe.
Competitive Landscape
With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)
4.2.2 Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies
4.2.3 Increasing Awareness Campaigns for DMD
4.3 Market Restraints
4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD
4.3.2 Stringent Regulatory Framework with High Product Cost Burden
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Therapeutic Approach and Treatment Type
5.1.1 Molecular-based Therapies
5.1.1.1 Mutation Suppression
5.1.1.2 Exon Skipping
5.1.2 Steroid Therapy
5.1.2.1 Corticosteroids
5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
5.1.4 Other Therapeutic Approaches and Treatment Types
5.2 By End User
5.2.1 Hospitals/Clinics
5.2.2 Ambulatory Centers
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 BioMarin
6.1.2 Bristol-Myers Squibb Company
6.1.3 Fibrogen Inc.
6.1.4 Eli Lilly and Company
6.1.5 Nobelpharma Co. Ltd
6.1.6 NS Pharma Inc.
6.1.7 Pfizer Inc.
6.1.8 PTC Therapeutics
6.1.9 Santhera Pharmaceuticals
6.1.10 Sarepta Therapeutics
7. Market Opportunities and Future Trends
By Therapeutic Approach and Treatment Type
Molecular-based Therapies
Mutation Suppression
Exon Skipping
Steroid Therapy
Corticosteroids
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Other Therapeutic Approaches and Treatment Types
By End User
Hospitals/Clinics
Ambulatory Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Durable Medical Equipment Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 10-06-2019
Market Overview
The durable medical equipment market is primarily driven by the rise of chronic diseases, technological advancements, and increasing government initiatives. The market is expected to witness a CAGR of 6.3% during the forecast period, owing to the well-developed healthcare infrastructure, the significant presence of multinational medical device companies, and well-planned reimbursement policies, among others.
The Asia-Pacific region is poised to register the fastest growth rate, due to the increasing R&D expenditure by governments and private companies in healthcare. Owing to a diversified patient population, the risk of life-threatening disorders in the region is high. Countries, such as China, Japan, and India, have witnessed an increased economic growth over the past five years, which has helped develop an improved healthcare infrastructure, thus, driving the growth of this market.
Scope of the Report
As per the scope of this report, durable medical equipment (DME) are the devices and products that serve medical purposes and that can tolerate frequent and/or subsequent usage. The patients now prefer availing post-operative and long-term care at home. Hence, the rising demand for home healthcare services opens possibilities for the DME market players to sell and cross-sell the various products.
Key Market Trends
Hospital/Clinic Segment holds the Largest Market Share and is Expected to Retain its Dominance
The hospital segment is expected to hold the maximum share in the global durable medical equipment market. The growth of the segment is mainly attributed to a high volume of patients coming to hospitals and greater financing capabilities.
Technological advancements in medical equipment are helping in the improvisation in diagnosis and treatment of diseases.
As development in the healthcare sector is being followed, there is an increase in the number of hospitals across the developing and developed nations. These increasing number of hospitals and clinics have well-equipped surgical equipment, such as wheelchairs, beds, walkers, bathroom safety devices, monitoring and therapeutic devices, and other equipment.
There is also a rising number of well-equipped diagnostic centers, which have equipment, such as blood sugar monitors, infusion pump, mattress and bedding devices, etc., that help in improving the total patient outcomes. There are also many insurance plans that reimburse the cost of repair and maintenance of the hospital medical equipment, and, therefore, a majority of hospitals are adopting these insurance policies. Therefore, the growth in the medical devices industry drives the hospital segment of the market
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America holds the largest share in the market, with the United States being the largest contributor to its revenue. In the United States, the Federal Drug and Food Administration (FDA) is responsible for regulating the sale of medical devices/products. The FDA also oversees the monitoring of safety in these regulated products. According to Select USA (a US government sponsored forum), the United States is the largest medical device market in the world. The country represents approximately 40% of the global medical device market. Overall, the United States is the largest market for durable medical equipment and may continue to retain its position over the forecast period. The main drivers of growth are likely to be the increasing population of elderly people and increasing chronic disease prevalence, which may indirectly fuel the adoption of durable medical equipment.
Competitive Landscape
The global durable medical equipment market is highly competitive and consists of several major players. The existing major players in the durable medical equipment market employ strong competitive strategies, leading to high rivalry between them. Some of the key players in the market are Compass Health Brands, GE Healthcare, Getinge AB, GF Health Products Inc., and Invacare Corporation, among others.The product advancements and improvements in durable medical equipment by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic and Lifestyle-related Disorders
4.2.2 Technological Advancements in Portability, Patient Comfort, and Utilities
4.2.3 Increasing Demand and Funding for Monitoring and Therapeutic Devices
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirements Related with Medical Supplies
4.3.2 Lack of Skilled Professionals and Shortage of Facilities
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Device Type
5.1.1 Personal Mobility Devices
5.1.1.1 Wheelchair
5.1.1.2 Crutch and Cane
5.1.1.3 Walker
5.1.1.4 Other Personal Mobility Devices
5.1.2 Medical Furniture and Bathroom Safety Devices
5.1.2.1 Medical Bed and Mattress
5.1.2.2 Commode and Toilet
5.1.2.3 Other Medical Furniture and Bathroom Safety Devices
5.1.3 Monitoring and Therapeutic Devices
5.1.3.1 Blood Glucose Monitor
5.1.3.2 Oxygen Equipment
5.1.3.3 Vital Sign Monitor
5.1.3.4 Infusion Pump
5.1.3.5 Other Monitoring and Therapeutic Devices
5.2 By End User
5.2.1 Hospital/Clinic
5.2.2 Ambulatory Surgical Center
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Compass Health Brands
6.1.2 GE Healthcare
6.1.3 Getinge AB
6.1.4 GF Health Products Inc.
6.1.5 Medtronic Inc.
6.1.6 Invacare Corporation
6.1.7 Masimo
6.1.8 Medline Industries Inc.
6.1.9 Koninklijke Philips NV
6.1.10 Sunrise Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Device Type
Personal Mobility Devices
Wheelchair
Crutch and Cane
Walker
Other Personal Mobility Devices
Medical Furniture and Bathroom Safety Devices
Medical Bed and Mattress
Commode and Toilet
Other Medical Furniture and Bathroom Safety Device
Monitoring and Therapeutic Devices
Blood Glucose Monitor
Oxygen Equipment
Vital Sign Monitor
Infusion Pump
Other Monitoring and Therapeutic Devices
By End User
Hospital/Clinic
Ambulatory Surgical Center
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
e-Health Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of e-health market include the growth in IoT and technological innovations, rising preference toward mobile technology and internet, and rising demand for population health management. Lifestyle-associated disorders, such as hypertension and diabetes, are expected to increase over the forecast period. These diseases raise the blood pressure and blood sugar levels. Thus, the increasing awareness among people about e-health and rising acceptance level among healthcare professionals, coupled with evidence of the efficiency of using this technology, are anticipated to result in substantial growth for this industry.
In recent years, the number of applications for internet in healthcare has increased exponentially. With the help the internet, healthcare professionals can deliver health information to health consumers more conveniently and in less time. Right from recording the patient entry to discharge, everything is being recorded with the help of the internet. IoT is propelling the market growth majorly in personal e-Health. IoT brings ease and convenience for healthcare providers, as well as for end users. Hence the adoption rate of incorporating it in healthcare is ever increasing, especially in developed countries.
Scope of the Report
As per the scope of the report, e-health is a promising field in public health and business, medical informatics, referring to health services, and information delivered or improved through the internet and related technologies. It empowers patients to take an active role in their treatment, allowing them to gain a deeper understanding of their conditions and how to effectively manage them.
Key Market Trends
Electronic Health Records (EHR) Segment is Expected to Grow the Fastest During the Forecast Period
EHR has been found dominating the overall market, which can be attributed to the growing adoption rate of EHR by many developed and developing countries, globally. EHR also improves the healthcare quality and offers convenience for healthcare providers, in terms of quick access to patient records, improved decision support, provides clinical alerts, and real-time quality reporting. These benefits have thus, contributed to the growth of EHR worldwide.
North American Region Holds the Largest Market Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is expected to be the largest market, due to the presence of technologically updated population base and various current initiatives taken in the region. These aforementioned factors are expected to be the drivers for the market growth. The high growth of this region has also been attributed to the availability of high-tech healthcare infrastructure, along with high-speed internet. Thus the rising awareness is expected to contribute substantially toward the development of the overall market.
Competitive Landscape
The rising focus of the players on technological developments and innovation is expected to fuel the growth of the overall market in the coming few years. As per the study, the competitive scenario of the global e-Health market is likely to intensify with an increasing number of players in the near future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in IoT and Technological Innovations
4.2.2 Rising Preference Toward Mobile Technology and Internet
4.2.3 Rising Demand for Population Health Management
4.3 Market Restraints
4.3.1 Concerns over Data Security
4.3.2 Lack of Reimbursement Policies in the Emerging Markets
4.3.3 Lack of Proper Infrastructure for e-Health in Emerging Markets
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Type of e-Health
5.1.1 Electronic Health Records
5.1.2 Health Information System
5.1.3 e-Prescribing
5.1.4 Clinical Decision Support Systems
5.1.5 Telemedicine
5.1.6 Other Types of e-Health
5.2 By Type of Service
5.2.1 Monitoring Services
5.2.1.1 Vital Sign Monitoring
5.2.1.2 Special Monitoring
5.2.1.3 Adherence Monitoring
5.2.2 Diagnosis Services
5.2.3 Other Types of Services
5.3 By End User
5.3.1 Hospitals
5.3.2 Insurance Companies
5.3.3 Healthcare Consumers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions, Inc.
6.1.2 athenahealth Inc.
6.1.3 Boston Scientific Corporation
6.1.4 Cerner Corporation
6.1.5 CompuMed Inc.
6.1.6 GE Healthcare
6.1.7 IBM
6.1.8 McKinsey & Company
6.1.9 Proteus Digital Health
6.1.10 Telecare Corporation
7. Market Opportunities and Future Trends
By Type of e-Health
- Electronic Health Records
Health Information System
e-Prescribing
Clinical Decision Support Systems
Telemedicine
Other Types of e-Health
By Type of Service
Monitoring Services
Vital Sign Monitoring
Special Monitoring
Adherence Monitoring
Diagnosis Services
Other Types of Services
By End User
Hospitals
Insurance Companies
Healthcare Consumers
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Electronic Medical Records Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| Unknown | Published: 25-06-2019 |
- Healthcare
- Mordor Intelligence
- pages
- Published: 25-06-2019
Market Overview
Electronic medical record (EMR) systems are becoming increasingly popular, as the healthcare industry is moving toward digitization. A lot of government initiatives, such as encouraging physicians to adopt electronic health records, investing in training the healthcare information technology workers, and establishing regional extension centers to provide technical and other advices are triggering the EMR market’s growth.
Moreover, factors, like rising need for integrated healthcare system, big data trends in healthcare industry, and technological advancements in the field of data storage are driving the growth of the EMR market. On the other hand, factors, like data privacy concerns, high initial investment, shortage of proper trained staff, and inter-operability issues are the primary restraints in the growth of the electronic medical records market.
Scope of the Report
Electronic health record (EHR) is a computerized version of paper record that stores information securely and is visible to other authorized users/practitioners. It is an electronic version of patient medical history, which is maintained and includes all data related to patients care under particular doctor, including demographics, progress notes, problems, medication and vital signs, past medical history, immunizations, laboratory data, and radiology reports.
Key Market Trends
The Cloud Based Segment Holds the Largest Share in the Electronic Medical Records Market
Based on mode of delivery, the electronic health record market is further segmented into cloud based and on-premise. Among these, cloud based holds the largest share in the electronic medical records market. This is attributed due to the rise in number of benefits, such as low licensing and start-up cost, low cost of maintenance and infrastructure requirements, and wider accessibility. In addition, a cloud-based EHR system provides enhanced productivity and faster and smoother implementation.
Based on end user, the electronic health record market is classified into hospital-based EMR and physician-based EMR. Hospital-based EMR held the largest share as an end-user segment in this market. The growth in this end-user segment is attributed to the increasing number of hospitals, globally, and several advantages associated with using EHR and easy availability of patient-centric data.
North America Dominates the Electronic Medical Records Market, Globally, During the Forecast Period
The healthcare IT market in the United States is one of the most established markets, compared to other geographical regions. Additionally, most hospitals and clinics in the region have widely implemented EHR solutions, due to stringent regulatory norms. Canada and the United States are the leading countries in this region that have implemented EHR systems. Asia-Pacific is anticipated to grow during the forecast period. Emerging countries, including India and China, have been experiencing strong economic growth. Increasing demand for the healthcare IT services and increasing expenditure by the governments in the emerging countries are expected to propel the EHR market in the Asia-Pacific region. In addition, China is the home for producing low-cost electronic components, which is anticipated to attract more investors.
Globally, governments have advised hospitals and clinics to change conventional health records into an electronic format for better storage of patient data. For instance, the U.S. government is taking initiatives to increase the use of EHR. The Health Information Technology for Economic and Clinical Health (HITECH) Act was authorized as a component of the American Recovery and Reinvestment Act (ARRA). This act was passed in 2009 to advance the utilization of EHR systems, with a specific end goal for modernizing and improving the healthcare system.
Competitive Landscape
Major market players in the global electronic health records market are actively participating in the development of new platform for the patient records. For instance, in May 2018, Cerner Corporation announced the agreement with Cerner Government Services Inc. for transitioning service members and their care providers’ access to a single electronic health record system. In April 2018, eClinicalWorks announced the partnership with Waverly Health Center (WHC), the partnership aimed to transform the WHC, Paragon Inpatient EHR system to the eClinicalWorks cloud-centric Acute Care EHR and Revenue Cycle Management platform.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Table of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Initiatives by the Governments
4.2.2 Technological Advancements
4.2.3 Low Maintenance and Wider Accessibility
4.3 Market Restraints
4.3.1 Data Privacy Concerns
4.3.2 High Initial Investment
4.3.3 Shortage of Proper Trained Staff
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Component
5.1.1 Hardware
5.1.2 Software
5.1.3 Services and Consulting
5.2 End User
5.2.1 Hospital-based EMR
5.2.2 Physician-based EMR
5.3 Functionality
5.3.1 Basic Systems
5.3.2 Fully Functional Systems
5.4 Application
5.4.1 Specialty Based
5.4.1.1 Cardiology
5.4.1.2 Neurology
5.4.1.3 Radiology
5.4.1.4 Oncology
5.4.1.5 Other Applications
5.4.2 General Applications
5.5 Type
5.5.1 Traditional EMRs
5.5.2 Speech enabled EMRs
5.5.3 Interoperable EMRs
5.5.4 Other Types
5.6 Mode of Delivery
5.6.1 Cloud Based
5.6.2 On-premise Model
5.7 Geography
5.7.1 North America
5.7.1.1 US
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 UK
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East & Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East & Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 eClinicalWorks
6.1.2 McKesson
6.1.3 Cerner Corporation
6.1.4 Allscripts
6.1.5 Meditech
6.1.6 GE Healthcare
6.1.7 Epic
6.1.8 Next Gen Healthcare
6.1.9 Greenway Health
*List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Component
Hardware
Software
Services and Consulting
End User
Hospital-based EMR
Physician-based EMR
Functionality
Basic Systems
Fully Functional Systems
Application
Specialty Based
Cardiology
Neurology
Radiology
Oncology
Other Applications
General Applications
Type
Traditional EMRs
Speech enabled EMRs
Interoperable EMRs
Other Types
Mode of Delivery
Cloud Based
On-premise Model
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Europe Cancer Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 70 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 70 pages
- Published: 17-06-2019
Market Overview
The propelling factors for the growth of the European cancer therapeutics market include the ease in regulatory approval for novel cancer therapy in Europe, increase in healthcare spending for cancer, rising prevalence of cancer, and strong R&D initiatives from key players.
The increasing cancer among the population represents the second most important cause of death and morbidity in Europe, accounting for 1.9 million deaths every year. According to WHO, Europe comprises only one-eighth of the total world population, but has around one-quarter of the total global cancer cases. Around 3.7 million new patients are being reported every year in Europe. There are also other factors attributed to the rising incidence of cancer in Europe, i.e. unhealthy lifestyles and inappropriate diet, obesity, and lack of physical activity. Thus, the growing incidence and prevalence of cancer is likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.
The direct cost of cancer has also increased, and thus the cost of cancer drugs as a share of direct health costs has doubled. The increase in the cost of the cancer treatment, along with the drugs prices, has resulted in the growth of the overall market.
In addition, the heavy investments made in R&D activities have enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence have boosted the market growth.
Scope of the Report
As per the scope of the report, cancer therapeutics are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells.
Key Market Trends
Target Therapy is the Largest Growing Segment under Therapy Type During the Forecast Period
The major factors driving the growth of the target therapy segment is the increase in R&D and the rising prevalence of various types of cancers. Targeted therapy is also gaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Thus, owing to the rising approval from regulatory bodies and an increase in the prevalence of all types of cancer, the segment is expected to witness a high growth rate over the forecast period.
Immunotherapies/biologics are also emerging as potential therapies to find a permanent cure for various cancer types among various cancer therapeutics.
Competitive Landscape
There are several big pharmaceutical companies present in the market that have started programs to help patients who are suffering from chronic diseases. Thus, there are many hospitals that are found collaborating with the pharmaceutical companies for the treatment and therapy of cancer. With such collaborations, the pharmaceutical companies are able to engage in larger studies that are aimed to speed up the pace of discovery of cancer therapeutics.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Ease in Regulatory Approval for Novel Cancer Therapy in Europe
4.2.2 Increase in Healthcare Spending for Cancer
4.2.3 Rising Prevalence of Cancer in Europe
4.2.4 Strong R&D Initiatives from Key Players
4.3 Market Restraints
4.3.1 Inequality in Access of Cancer Therapy across Europe
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Target Therapy
5.1.3 Immunotherapy (Biologic Therapy)
5.1.4 Hormonal Therapy
5.1.5 Other Treatment Types
5.2 By Cancer Type
5.2.1 Blood Cancer
5.2.2 Breast Cancer
5.2.3 Prostate Cancer
5.2.4 Skin Cancer
5.2.5 Respiratory/Lung Cancer
5.2.6 Other Cancer Types
5.3 By End User
5.3.1 Hospitals
5.3.2 Specilty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.4 Geography
5.4.1 Europe
5.4.1.1 Germany
5.4.1.2 UK
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Bristol-Meyrs Squibb Company
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Chemotherapy
Target Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Other Treatment Types
By Cancer Type
Blood Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Respiratory/Lung Cancer
Other Cancer Types
By End User
Hospitals
Specilty Clinics
Cancer and Radiation Therapy Centers
Geography
Europe
Germany
UK
France
Italy
Spain
Rest of Europe